Aurobindo Pharma has posted its highest-ever quarterly revenue of Rs 10,263 crore for the second quarter of FY27, registering a robust 23.9% year-on-year growth, driven by strong performance across its key markets.

 

The pharmaceutical major also reported a 32.5% jump in net profit to Rs 1,124 crore for the quarter ended September 30, 2026, compared with Rs 848 crore in the corresponding quarter of the previous financial year.

 

The company's operating performance strengthened further, with EBITDA, before forex and other income, climbing 28.5% to Rs 2,156 crore from Rs 1,678 crore a year ago.

 

EBITDA margin improved to 21%, against 20.3% in Q2FY26, marking an expansion of 75 basis points.

 

Profit before tax, before accounting for the share of profit or loss of joint ventures, rose 32.7% to Rs 1,691 crore, compared with Rs 1,274 crore in the year-ago quarter.

 

The US continued to be Aurobindo Pharma's largest growth engine, with revenue surging 25% year-on-year to Rs 4,555 crore (USD 477 million).

 

Europe delivered an equally strong performance, posting a 27% increase in revenue to Rs 3,161 crore (EUR 288 million).

 

Revenue from Growth Markets rose 16% to Rs 1,026 crore (USD 107 million), while anti-retroviral (ARV) revenue stood at Rs 359 crore (USD 38 million).

 

The broad-based growth across geographies helped the company achieve its highest-ever quarterly revenue.

 

Aurobindo Pharma received final approval from the US Food and Drug Administration (USFDA) for 12 products during the quarter.

 

The company spent Rs 376 crore on research and development (R&D), up from Rs 344 crore in the preceding quarter, reflecting its continued investment in product development and its pipeline.

 

Aurobindo generated free cash flows of USD 146 million during the quarter, even after accounting for strategic capital expenditure investments. Its net cash position, including investments, stood at USD 189 million as of September 30, 2026.